{
  "id": 18333392,
  "title": "Revolution’s Rasonque off to best cancer drug launch ‘in history’",
  "url": "https://urgent.news/2026/11/05/revolutions-rasonque-off-to-best-cancer-drug-launch-in-history",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-05T16:21:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/revolution-rasonque-sales-3q-2026-pancreatic-cancer/873839/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Revolution Medicines reported that its pancreatic cancer drug, Rasonque, generated $198 million in sales within five weeks of its U.S. approval. According to STAT News, more than 5,000 patients have been treated with the pan-RAS inhibitor. The sales performance was nearly double the most optimistic investor estimates prior to the company's third-quarter earnings announcement.\n\nWhile STAT News described the commercial debut as eye-popping, Revolution Chief Commercial Officer Anthony Mancini stated during an earnings call that the U.S. launch is off to a strong start. BioPharma Dive reports that Wall Street analysts are resetting projections for the drug, though company executives cautioned that it is too early to draw conclusions regarding its launch trajectory.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "STAT News",
        "title": "STAT+: Revolution Medicines’ pancreatic cancer drug has stunning commercial debut",
        "url": "https://urgent.news/2026/11/05/stat-revolution-medicines-pancreatic-cancer-drug-has-stunning",
        "published": "2026-11-05T12:33:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}